Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.
Bracarda S, Galli L, Maruzzo M, Lo Re G, Buti S, Favaretto A, Di Costanzo F, Sacco C, Merlano M, Mucciarini C, Zafarana E, Romito S, Maestri A, Giorgio CG, Ionta MT, Turci D, De Giorgi U, Procopio G, Cortesi E, Giannarelli D, Porta C.
Bracarda S, et al. Among authors: giorgio cg.
Future Oncol. 2018 Jun;14(14):1347-1354. doi: 10.2217/fon-2017-0570. Epub 2018 May 18.
Future Oncol. 2018.
PMID: 29774766